Modern medicines for obesity have changed the way many people think about weight management. Several drugs can now help patients lose much more weight than older treatments, leading to excitement among doctors and the public.
Yet an important new review published in The BMJ shows that losing more weight does not always mean better overall health. The researchers found that although several medicines produced remarkable weight loss, improvements in quality of life were often modest, while side effects became more common as weight loss increased.
To reach these conclusions, researchers analyzed 262 randomized clinical trials involving nearly 100,000 adults with overweight or obesity. They compared 19 different medicines against placebo, lifestyle treatment, or other weight-loss drugs. This allowed them to evaluate which medicines performed best across many different health outcomes.
The strongest weight-loss results came from tirzepatide and CagriSema, followed by oral semaglutide, injectable semaglutide, orforglipron, and phentermine-topiramate. Several newer medicines also appeared promising, but researchers noted that the evidence supporting them remains uncertain because relatively few studies have been completed.
Weight loss, however, was only one part of the picture. The investigators also measured body fat, muscle mass, serious heart events, kidney disease, quality of life, and unwanted side effects. They found that medicines producing the greatest weight loss also tended to cause more nausea, vomiting, diarrhea, fatigue, and treatment discontinuation.
Another important finding involved muscle loss. Tirzepatide produced the greatest reduction in body fat but also the largest loss of lean tissue. Since muscle helps maintain strength, balance, and physical function, preserving it is especially important for older adults.
The review found limited evidence that most medicines greatly improved patients’ daily quality of life. Only injectable semaglutide showed convincing reductions in deaths from any cause, heart attacks, and heart failure, while tirzepatide lowered heart failure risk. No medicine clearly reduced kidney failure.
The researchers also pointed out that obesity treatment is usually a long-term commitment. Many patients regain weight after stopping medication, suggesting that continuing treatment may be necessary to maintain benefits.
The authors conclude that choosing an obesity medicine should involve careful discussions between patients and healthcare professionals. Decisions should include expected weight loss, possible side effects, long-term safety, costs, access, and personal treatment goals rather than focusing only on the number shown on the scale.
This review provides one of the clearest comparisons currently available because it combines evidence from hundreds of randomized clinical trials. Nevertheless, important uncertainties remain because many studies were relatively short and several new medicines have only limited supporting data.
The findings remind us that successful obesity treatment involves much more than losing weight. Long-term health, quality of life, muscle preservation, cardiovascular protection, affordability, and patient preferences all deserve equal attention when choosing the best treatment.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies about a simple path to weight loss, and results showing a non-invasive treatment for obesity and diabetes.
Source: The BMJ.
